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Abstract The non-selective gastrin/eholeeystokinin receptor an- 
tagonists proglumide and benzotript inhibit colon carcinoma cell 
proliferation by binding to the 78 kDa gastrin-binding protein 
(GBP) (Baldwin, Proc. Natl. Acad. Sci. USA, 91 (1994) 7593- 
7597). However, although most colon carcinoma cell lines synthe- 
size progastrin, production of mature amidated gastrin~7 has not 
been observed. In order to define the structural requirements for 
the binding of gastrin to the GBP the affinities of various frag- 
ments of amidated amd C-terminally extended gastrin~7 for the 
GBP have been measured. The results indicate that the GBP 
recognizes both N- and C-termini of gastrin~7. Moreover since 
C-terminal amidation is not a prerequisite for binding of gastrin 
to the GBP, the GBP is a potential target for the autocrine effects 
of progastrin. 
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1. Introduction 
dated gastrin~7 as shown in Fig. 1 [13-15], a candidate receptor 
for autocrine gastrin should not require an amidated C-termi- 
nus for binding. A cell-surface receptor binding glycine-ex- 
tended gastrin2 17 and capable of stimulating proliferation of 
the rat pancreatic carcinoma cell line AR4-2J has recently been 
reported [16]. Both binding and proliferation were uneffected 
by gastrinl7 or by the gastrin/CCK-B receptor antagonists, 
L365,260 and PD 134,308. The affinity of the non-selective gas- 
trin/CCK receptor antagonists proglumide and benzotript for 
the new receptor, and its structural relationship to other mem- 
bers of the gastrin/CCK receptor family, has not been reported 
yet. 
Since the GBP is the target for the anti-proliferative effects 
of proglumide and benzotript on colon carcinoma cell lines [8], 
the structural requirements for binding of gastrin to the GBP 
were investigated, and are reported in the present paper. In 
particular the observation that the affinity of the GBP for 
glycine-extended gastrin~7 is very similar to the affinity for gas- 
trine7 implies that the GBP is a potential target for the autocrine 
effects of progastrin. 
Although evidence is accumulating that colorectal carcino- 
mas utilize progastrin as an autocrine growth factor, there has 
been some dispute over the receptor involved [1]. Based on 
reports of high affinity gastrin receptors on the mouse colon 
carcinoma cell line MC26 [2] and on over 50% of primary 
human colon cancer specimens [3], it has often been assumed 
that the autocrine loop utilizes a gastrin/cholecystokinin 
(CCK)-B receptor. However the majority of colon carcinoma 
cell lines express only gastrirdCCK-C receptors, which have a 
low affinity for gastrin [4-6]. In addition the observation that 
the CCK-A receptor-selective antagonist, L364,718, and the 
gastrin/CCK-B selective antagonist, L365,260, had no effect on 
colon carcinoma cell proliferation at concentrations sufficient 
to saturate their respective receptors uggested that neither the 
A nor the B receptor participated in the autocrine loop [7]. The 
gastrin/CCK-C receptor, which is the target for the inhibitory 
effects of gastrin/CCK receptor antagonists on colon carci- 
noma cell proliferation [5], is identical to a 78 kDa gastrin- 
binding protein (GBP) [8]. The GBP, which has been purified 
from porcine gastric mucosal membranes [9,10], is a member 
of the family of fatty acid oxidation enzymes possessing enoyl 
CoA hydratase and 3-hydroxyacyl CoA dehydrogenase activi- 
ties [11]. 
Since colon carcinoma cell lines synthesize progastrin, but 
fail to process the prohormone to mature C-terminally ami- 
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Abbreviations: CCK, cholecystokinin; GBP, gastrin-binding protein; 
IC50, concentration required for 50% inhibition of cross-linking. 
2. Experimental 
2.1. Materials 
Gastrin~7 was from Research Plus, Bayonne, NJ. The purity and 
composition of gastrin-related peptides was assessed by the manufac- 
turer (Chiron Mimotopes, Clayton, Australia) by reversed phase high 
pressure liquid chromatography and by ion spray mass spectrometry, 
respectively. Pepstatin, benzamidine, hexamethylphosphoramide and 
aprotinin were from Sigma, St.Louis, MO. Na~25I was from NEN, 
North Ryde, Australia. 
2.2. Gastrin cross-link&g assay 
The 78 kDa GBP was partially purified from detergent extracts of 
porcine gastric mucosal membranes by lectin and ion-exchange chrom- 
atography [9,10]. The following protease inhibitors were included in all 
buffers to prevent proteolysis: pepstatin 1/2M, benzamidine 1mM, 
hexamethylphosphoramide 0.1% (w/v), aprotinin 500 units/ml. 
Crosslinking of [~:5I]Nle~5-gastrin2 ~7 to the GBP with disuccin- 
imidylsuberate was measured as described previously [9] in the presence 
of increasing concentrations ofgastrin analogues. The products of the 
cross-linking reaction were separated by polyacrylamide gelelectropho- 
resis, and radioactivity associated with the 78 kDa GBP was detected 
and quantitated with a phosphorimager (Molecular Dynamics, Sun- 
nyvale, CA). Initial estimates of IC50 values, and of the levels of 
[~25I]gastrin2 ~7 bound in the absence of competitor, were obtained by 
fitting the data with the program EBDA, and were refined with the 
program LIGAND as described previously [4]. 
3. Results 
3.1. Amidation of gastrinl7 is not required for GBP binding 
The effect of extending the C-terminus ofgastrin~7 on binding 
to the GBP was investigated by comparing the potencies of 
glycine-extended gastrinj7 (Fig. 1) and gastrin17 as inhibitors of 
cross-linking of [lzSI]Nle~5-gastrin2 ~7 to the GBP. The ICso 
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Fig. 1. Processing and sequences of gastrin-related peptides. The C-terminal sequence of human progastrin is shown in the one letter code. The 
corresponding region of porcine progastrin isonly shown where it differs from human progastrin. Processing begins by cleavage by a dibasic-specific 
endopeptidase at the sites marked by arrowheads [12]. Removal of the basic amino acids by carboxypeptidase E yields glycine-extended gastrin17 
(gastrin~_17G), which is transamidated by peptidyl-glycine ct-amidating monooxygenase to form mature amidated gastrin~_17. The indicated peptides 
(numbered from the N-terminus of gastrinl ~7) were synthesized according to the human sequence, with the N-terminal glutamic acid of gastrinl~, 
gastrinl u, gastrint 17 and gastrin~ 17 G cyclized to pyroglutamate. The C-termini of gastrinl_~7 and gastrin~4_17 were amidated. 
value for glycine-extended gastrin17 was slightly lower than the 
ICso value for gastrinl7 (Fig. 2, Table 1). Addition of a further 
5 residues to the C-terminus of glycine-extended gastrins_: 
did not alter the affinity of the resultant peptide for the GBP, 
while addition of 5 residues to the C-terminus of glycine-ex- 
tended gastrin~2_17 actually resulted in a 25-fold reduction in 
affinity. 
3.2. Gastrin17 binding determinants 
The regions of gastrinl7 contributing to GBP binding were 
investigated by testing the effect of N- and C-terminal deletion 
on the potency of glycine-extended gastrinl7 as an inhibitor of 
cross-linking of [125I]Nle~5-gastrin2_17 to the GBP. Removal of 
4 or 11 residues from the N-terminus of glycine-extended gas- 
t r in :  resulted in 140- and 160-fold increases, respectively, in the 
IC50 value for inhibition of cross-linking of [125I]NlelS-gastrin2.17 
to the 78 kDa GBP (Fig. 2, Table 1). Similarly removal of 7 
residues from the C-terminus of glycine-extended gastrini7 re- 
suited in a 110-fold reduction in affinity. Removal of a further 
7 residues from the C-terminus of glycine-extended gastrinl7 
resulted in almost complete loss of binding affinity. 
4. Discussion 
4.1. Comparison of gastrin receptor binding sites 
Comparison of the affinities of gastrin analogues for the 78 
kDa GBP revealed that both ends of gastrin~7 contribute to 
binding. Thus removal of 4 residues (pyroglutamylGPW) from 
the N-terminus of glycine-extended gastrin: resulted in a 
140-fold decrease in affinity, while removal of 7 residues 
(YGWMDFG) from the C-terminus of glycine-extended gas- 
trin17 resulted in a 110-fold decrease in affinity (Table 1). In 
reciprocal experiments he binding of the deleted peptides to 
the GBP was also measured. As expected gastrin~_17 bound 
weakly to the GBP, but binding of the N-terminal tetrapeptide 
pyroglutamylGPW was barely detectable. Since benzotript, he 
best available antagonist for the GBP [8], is an acylated trypto- 
phan derivative (N-4-chlorobenzoyl-L-tryptophan), it seems 
likely that the tryptophan residue of either the N-terminal or 
C-terminal tetrapeptide, or both, makes a significant contribu- 
tion to binding. 
The role of the five glutamic acid residues of gastrinl 7in GBP 
binding is not clear at present. The similar affinities of glycine- 
extended gastrin~17 and glycine-extended gastrin12_17 for the 
GBP (Table 1) suggest that the polyglutamate s quence makes 
no contribution. However, deletion of the five glutamate resi- 
dues from gastrinl 11 to yield gastrinl~ resulted in a 60-fold 
decrease in affinity. 
In contrast o the present results with the GBP, two lines of 
evidence demonstrate that the gastrin/CCK-B receptor does 
not recognize the N-terminus of gastrin17. Firstly no binding of 
the N-terminal tridecapeptitte to the gastrin/CCK-B receptor 
on canine parietal cells was observed even at concentrations a
high as 100 pM [17]. Secondly removal of 4 residues from the 
N-terminus of gastrin17 had no effect on binding to rabbit 
parietal cells [18]. The observation that removal of a further 
5 residues, including 4 of the 5 glutamic acid residues, reduced 
binding to rabbit parietal cells by 100-fold additionally implied 
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Fig. 2. Binding of gastrin-related peptides to the 78 kDa GBR Cross- 
linking of [125I]NlelS-gastrin2_17 to the 78 kDa GBP was measured as 
described in section 2 in the presence of increasing concentrations of 
gastrin-related peptides. Duplicate samples were subjected to electro- 
phoresis on NaDodSO4-polyacrylamide gels and the radioactivity asso- 
ciated with the 78 kDa GBP was quantitated by phosphorimager scan- 
ning (insets), and expressed as a percentage ofthe value obtained in the 
absence of competitor. The following values for ICs0 and for the pre- 
dicted ordinate intercept were obtained by computer fitting as described 
previously [4], and used to construct the indicated lines of best fit: 
(A) gastrin~_17 (138 nM, 115.5%) or glycine-extended gastrin~ 17 (98 nM, 
90.0%); (B) glycine-extended gastrin 5 t7 (11 //M, 93.8%) or glycine- 
extended gastrin12 ~7 (40 /.tM, 99.6%); or (C) gastrinl~ (1.96 mM, 
101.7%) or gastrin~_~ (31/2M, 101.3%). These values were averaged 
with the results of two similar experiments to obtain the mean values 
presented in Table 1. 
that the pentaglutamic acid sequence contributed to gas- 
t r in /CCK-B receptor binding [18]. The gastrin binding sites 
of the GBP and the gastrin/CCK-B receptor are thus clearly 
distinct. 
4.2. Role of  progastrin in colorectal carcinoma growth 
There is now abundant evidence that colorectal carcinomas 
produce progastrin, but fail to process it into mature amidated 
gastrin. Gastrin mRNA has been demonstrated in both normal 
and neoplastic olorectal mucosa by Northern blotting [15], 
and in colon carcinoma cell lines by PCR [15,19,20]. The levels 
of gastrin mRNA detected by quantitative PCR were always 
less than 1 molecule/cell [20]. At the peptide level gastrin im- 
munoreactivity was detected in 21% of colonic tumours [21]. 
More recently both progastrin and gastrin were detected by 
immunohistochemistry in more than 80% of the tumour cells 
in 20/23 colorectal adenocarcinomas, whereas in normal co- 
Ionic mucosa only occasional crypt cells stained simultaneously 
for progastrin and gastrin [22]. An increase in progastrin pro- 
duction in colorectal tumour tissue compared to normal mu- 
cosa has also been demonstrated in tissue extracts [14, 
15]. In contrast o the immunohistochemical results levels of 
mature gastrin were low, and did not differ between normal 
and tumour tissue [13-15]. Although an early report indicat- 
ed that all 5 colonic carcinoma cell lines tested secreted 
gastrin immunoreactivity [23], more recent work revealed 
that all (5/5) colonic carcinoma cell lines tested produced 
progastrin, but that mature amidated gastrin was not present 
[151. 
Any gastrin receptor participating in an autocrine loop in 
colon carcinoma cells must therefore be capable of recognizing 
C-terminally extended forms of gastrin. One possible candidate 
is the receptor for glycine-extended gastrin2 17 recently de- 
scribed by Seva and coworkers [16] on the surface of the rat 
pancreatic carcinoma cell line AR4-2J. The new receptor binds 
glycine-extended gastrin2_~7 with high affinity (Kd = 0.45 nM), 
but does not recognize gastrinlT, CCK8 or the gastrin/CCK-B 
receptor-selective antagonists L365,260 and PD 134308. The 78 
kDa GBP also fits the requirements for the autocrine receptor, 
since it binds glycine-extended forms of gastrin with similar 
affinity to mature amidated gastrins (Table 1). Although the 
affinity of the GBP for gastrinl7 is low (230 nM), the intracellu- 
lar concentration of progastrin may be considerably higher 
than has been supposed previously, as discussed in a later 
section. Further C-terminal extension of glycine-extended gas- 
trin5 17 did not change its affinity for the GBP, while extension 
of glycine-extended gastrina2_~7 resulted in a 25-fold reduction 
in affinity (Table 1). In contrast o the GBP the gastrin/CCK-B 
receptor on canine parietal cells has much lower affinity for 
Table 1 
Affinities of gastrin-related peptides for gastrin receptors 
Peptide Purity ICso (~M) 
(%) 
78 kDa Gastrin/ 
Gastrin- CCK-B 
binding receptor 
protein 
Gastrin~_17 82 0.23 - 0.15 5 X 10 -4 
Gastrinl_lTG 78 0.19 + 0.10 ND 
Gastrins_~TG 93 26 + 15 ND 
Gastrins_~TGRRSAE 87 20 + 11 ND 
Gastrin12_lTG 81 31 + 17 14 + 71 
Gastrinl~_17GRR ND ND 44 + 21 
Gastrinl2_j7GRRSAE 91 760 + 550 ND 
Gastrin14_: 95 370 + 280 0.1 
Gastrinj_H 97 21 + 9 ND 
Gastrinj_4 98 > 1000 ND 
YFGRRSAEDEN 62 105 _+ 21 ND 
ICs0 values (mean + S.D. of at least 3 separate determinations, one of 
which is shown in Fig. 2) for the inhibition of cross-linking of[~25I]N1e ~5- 
gastrin2 17 to the 78 kDa gastrin-binding protein by the indicated pep- 
tides were determined asdescribed in the legend to Fig. 2. IC50 values 
for gastrinj2_17GRRSAE , gastrint~ and YFGRRSAEDEN should be 
regarded as estimates only because the limiting amounts of peptide 
available precluded assay at concentrations greater than 100, 400 and 
100/tM, respectively. ICs0 values for the gastrirdCCK-B receptor on 
canine parietal cells, and for the binding of gastrina_17 and gastrin~¢ ~7 
to the GBP, are taken from [17] and [8], respectively. The amino acid 
sequences of C-terminal extensions are shown in the one letter code; 
peptide sequences are shown in full in Fig. 1. 
100 G.S. Baldwin/FEBS Letters 359 (1995) 97-100 
glycine-extended gastrin12_17 than for mature amidated gastrins 
[17] (Table 1). Thus the affinities of the 78 kDa GBP and the 
gastrin/CCK-B receptor for glycine-extended gastrin~2_~7 are 
similar (31 /.tM and 14/,tM respectively), despite a 400-fold 
difference in their affinities for gastrin17 (0.5 nM and 0.2 ~tM, 
respectively). A critical experiment in deciding which receptor 
is involved in the autocrine loop will be comparison of the 
affinities of all known gastrin/CCK receptors for full-length 
progastrin. However, the length of the prohormone (104 amino 
acids) has precluded organic synthesis, and will necessitate 
progastrin expression in, and purification from, bacterial or 
baculovirus ystems. 
Interestingly the intracellular concentration of progastrin in 
colon carcinoma cells reaches/~M levels. Values for extracts 
from 5 different cell lines ranged from 17 to 54 fmol/106 cells 
[15]. Assuming a cell diameter of 20/tm, and an even distribu- 
tion of progastrin throughout the cell, the internal concentra- 
tions of progastrin are in the range 4 to 13/tM. If the intracel- 
lular population of the 78 kDa GBP is accessible to progastrin, 
and if the binding affinity for progastrin is similar to glycine- 
extended gastrin17, then the percent saturation will be between 
95% and 98%. Although the gastrin/CCK-B receptor would 
also be saturated by the levels of progastrin present within 
colon carcinoma cell lines, receptor expression in this case is 
limited to the cell surface. In conclusion previous data on ag- 
onist and antagonist affinities [8], and the present report that 
the GBP binds glycine-extended gastrin~7 with an affinity simi- 
lar to gastrin~7, are consistent with the conclusion that the GBP 
is the target for the autocrine ffects of progastrin in colonic 
carcinoma. 
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